Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia
Authors:
Open Access
- 18 March 2025
- journal article
- case report
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (4) , 2545-2549
Abstract
Nucleoporin 98 (NUP98) fusion oncoproteins are associated with various hematologic malignancies. Acute myeloid leukemia (AML) with NUP98-NSD1 typically co-occurs with FLT3-ITD mutations, exhibiting poor initial responses to traditional chemotherapy. This case report describes a relapsed and refractory AML case co-expressing NUP98/NSD1 and FLT3/ITD after matched sibling haplo-identical allogeneic hematopoietic stem cell transplantation, achieving molecular remission with a salvage therapy combining selinexor, venetoclax, and azacitidine. To our knowledge, this is the first report demonstrating the effectiveness of this combination therapy for relapsed/refractory NUP98-NSD1+/FLT3-ITD + AML. This report highlights the potential synergy between selinexor and established AML therapies, suggesting a promising approach to improve outcomes for refractory AML patients.Keywords
This publication has 30 references indexed in Scilit:
- Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCTAnnals of Hematology, 2022
- Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusionsInternational Journal of Hematology, 2019
- Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 studyInternational Journal of Hematology, 2018
- NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive LeukemogenesisCancer Cell, 2016
- NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML groupLeukemia, 2016
- NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosisLeukemia, 2016
- Acute myeloid leukemia with NUP98–HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature reviewCancer Genetics and Cytogenetics, 2009
- Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD fingerNature, 2009
- Cryptic translocation t(5;11)(q35;p15.5) with involvement of the NSD1 and NUP98 genes without 5q deletion in childhood acute myeloid leukemiaGenes, Chromosomes and Cancer, 2002
- The peptide repeat domain of nucleoporin Nup98 functions as a docking site in transport across the nuclear pore complexCell, 1995